On today’s episode of Free Lunch, Associate Stock Strategist Ryan McQueeney chats with Dave Bartosiak about the marijuana investing craze and how to properly value pot stocks. He also recaps the latest trade war news and recaps analyst notes on Tesla, Roku, and Micron.
Want more video content from Zacks? Subscribe to
Zacks Investment News now!
Free Lunch is the newest show from Zacks Investment Research. It is streamed live, four times per week, and features breaking news and analysis from Zacks strategists. Free Lunch is available on YouTube, Facebook Live, Twitter, Ustream, and more.
American stocks were able to rally into the green in early trading, but many global markets were down as the ongoing trade war between the U.S. and China was expected to escalate again, with Chinese regulators responding to President Trump’s latest tariff plan by digging up an anti-dumping dispute which it has previously brought to the World Trade Organization.
Elsewhere, analysts were busy Tuesday morning, and Wall Street had a plethora of fresh notes to digest. Notably, Nomura downgraded Tesla (
TSLA - Free Report) , citing Elon Musk’s “erratic behavior” and blaming him for an onslaught of key executive departures at the company.
Wall Street appears to also be getting more cautious about Micron (
MU - Free Report) , which saw its price target cut by RBC Capital today as yet another firm warns investors about how headwinds like DRAM pricing could soon cut the memory giant’s growth cycle short.
But it was not all bad on Tuesday, as KeyBanc Capital analysts raised their price target for Roku (
ROKU - Free Report) on the back of continued expansion from the Roku Channel and its unique opportunities to spur acquisition and marketing initiatives.
On the first half of today’s show, Ryan discusses the latest trade war news and recaps all of these analyst notes.
Later, he is joined by Zacks Strategist Dave Bartosiak to discuss recent happenings in the world of marijuana investing.
Shares of Canadian cannabis producer Tilray (
TLRY - Free Report) surged on Tuesday morning after it announced that one of its medical products was successfully imported into the United Kingdom. This type of international expansion is exciting not only for Tilray, but also for other pure-play marijuana companies looking to grow as regulations around the world shift.
The potential for nearly unlimited global expansion has marijuana investors extremely amped up about their industry of choice, but is it possible that this buzz is creating a bubble? How do intelligent investors filter out the noise and make smart decisions in the marijuana business? Make sure to check out the show as Ryan and Dave attempt to answer these very questions!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>